QUEBEC CITY, May 28, 2013 /PRNewswire/ -DiagnoCure Inc. (TSX: CUR)
(OTCQX: DGCRF) announced today that it will release its second quarter
2013 results on June 3, 2013, at 4:00 p.m. (EDT). DiagnoCure's
management will host a conference call the same day, at 4:30 p.m.
(EDT). Interested participants may listen to the call by dialing
1-888-231-8191 or 514-807-9895 and referencing code 77464078
approximately 15 minutes prior to the call. The Corporation will also
provide a live webcast of the call. Interested participants may access
the webcast on DiagnoCure's website at www.diagnocure.com, through a link on the Investors page - Presentations. A replay of the
webcast will be available on DiagnoCure's website for those unable to
participate in the live webcast.
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that
develops and commercializes high-value cancer diagnostic tests that
increase clinician and patient confidence in making critical treatment
decisions. In 2008, the Corporation launched a colorectal cancer
staging test through its U.S. CLIA laboratory. PrevistageTM GCC is
currently available for licensing. The Corporation has granted a
worldwide exclusive license to Gen-Probe, now a wholly-owned subsidiary
of Hologic Inc. operating as Hologic Gen-Probe, for the development and
commercialization of a prostate cancer test using PCA3, DiagnoCure's
proprietary molecular biomarker. Hologic Gen-Probe's PROGENSA® PCA3
test is commercialized in Europe under CE mark and is approved for
commercialization in Canada and the United States. For more
information, please visit www.diagnocure.com.
This release contains forwardlooking statements that involve known and
unknown risks, uncertainties and assumptions that may cause actual
results to differ materially from those expected. By their very nature,
forwardlooking statements are based on expectations and hypotheses and
also involve risks and uncertainties, known and unknown, many of which
are beyond DiagnoCure's control. As a result, investors are cautioned
not to place undue reliance on these forwardlooking statements. The
forward-looking statements regarding the outcome of research and
development projects, clinical studies and future revenues are based on
management expectations. In addition, the reader is referred to the
applicable general risks and uncertainties described in DiagnoCure's
most recent Annual Information Form under the heading "Risk Factors".
DiagnoCure undertakes no obligation to publicly update or revise any
forwardlooking statements contained herein unless required by the
applicable securities laws and regulations.
SOURCE DiagnoCure inc.